Itrazol Caps (Itraconazole)

Itraconazole is an azole antifungal used to treat systemic fungal infections and related conditions.

• Candidiasis: effective for oral, esophageal and systemic candidal infections, reducing fungal burden.
• Aspergillosis: used in invasive aspergillosis to inhibit growth of Aspergillus species.
• Histoplasmosis: indicated for treatment of acute and chronic histoplasma infections.
• Systemic mycoses: employed in various deep‑tissue mycoses such as blastomycosis and sporotrichosis.

• Itraconazole inhibits the fungal enzyme lanosterol 14α‑demethylase, a cytochrome P450 isozyme essential for converting lanosterol to ergosterol. By blocking ergosterol synthesis, the drug disrupts fungal cell membrane formation, leading to increased membrane permeability and inhibition of fungal growth. The inhibition is concentration‑dependent and persists after drug removal, providing a prolonged antifungal effect. Itraconazole also exhibits activity against a broad spectrum of yeasts and molds, making it suitable for both superficial and invasive infections.

Itraconazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild stomach upset often after the first doses.
• Headache: transient headache reported in many patients.
• Rash: mild skin erythema or itching.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or hepatitis requiring monitoring.
• Cardiac failure: rare cases of congestive heart failure, especially in patients with pre‑existing heart disease.
• Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome.

When prescribing Itraconazole, clinicians should consider several precautionary measures to ensure safe use.

• Liver function: assess baseline hepatic enzymes and monitor periodically during therapy.
• Drug interactions: review concomitant medications that affect CYP3A4 metabolism.
• Cardiac status: evaluate for existing heart failure before initiating treatment.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Renal impairment: adjust dosing in severe renal dysfunction as recommended.
• Store at ambient temperature: keep capsules below 25 °C in the original container, protected from moisture and light.

Itraconazole has a notable interaction profile due to its effect on cytochrome P450 enzymes.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce itraconazole exposure.
• Certain statins (e.g., simvastatin, lovastatin): increased risk of myopathy and rhabdomyolysis.
• QT‑prolonging agents (e.g., quinidine, sotalol): additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin): may enhance anticoagulant effect, requiring INR monitoring.
• Oral contraceptives: possible reduction in contraceptive efficacy, advise backup method.
• Proton pump inhibitors: may decrease absorption of itraconazole, consider timing adjustments.